Seagen clinical trials

Acquired by Pfizer, Dec 14, 2023 · source ↗

The registry lists 30 studies whose lead sponsor is Seagen. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.

Studies

Recruiting first, then most recently updated. Showing 30 of 30. All Pfizer studies →

• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingNCT04879329Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsRecruitingNCT06131840Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingNCT05253651Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesActive, not recruitingNCT04227847Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionCompletedNCT04569032Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerActive, not recruitingNCT06012435Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingNCT03975647Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingNCT06157892Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminatedNCT03786081Phase 1/2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruitingNCT03485209Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLActive, not recruitingNCT04404283Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of SGN-MesoC2 in Advanced Solid TumorsTerminatedNCT06466187Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted after Seagen became part of Pfizer

• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersTerminatedNCT06254495Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted after Seagen became part of Pfizer

• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsTerminatedNCT05571839Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsTerminatedNCT05983133Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersActive, not recruitingNCT04430738Phase 2

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerCompletedNCT04697628Phase 3

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted after Seagen became part of Pfizer

• HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyCompletedNCT05902494

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer

• Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerApproved for marketingNCT04220203

  Sponsor listed in the registry: Seagen, a wholly owned subsidiary of Pfizer · First submitted before Seagen became part of Pfizer